Finasteride and Trazodone Interaction: What Patients and Clinicians Need to Know

Are Finasteride and Trazodone Safe to Take Together?

Co-administration of finasteride and trazodone is generally considered low-to-moderate risk, not contraindicated. The two drugs share no clinically proven pharmacokinetic interaction at approved doses, but both carry independent adverse-effect profiles that may amplify each other, specifically dizziness, orthostatic hypotension, and sedation. Patients on both agents need counseling about fall risk and CNS depression rather than automatic discontinuation of either drug.

Why This Combination Comes Up Clinically

Finasteride at 1 mg/day (Propecia) is prescribed for male androgenic alopecia, and at 5 mg/day (Proscar) for benign prostatic hyperplasia (BPH). The BPH population skews older, overlapping heavily with the age group for whom trazodone is commonly prescribed as a sleep aid at 50-100 mg at bedtime or as an antidepressant at doses up to 400 mg/day. Because both drugs appear on the same medication lists for men over 50, clinicians regularly field questions about their combined safety.

The FDA label for finasteride (Propecia) notes no specific interaction studies with trazodone, which is consistent with the limited CYP overlap at therapeutic plasma concentrations. The finasteride prescribing information is available via FDA. [1]

Pharmacokinetics: How Each Drug Is Metabolized

Understanding the metabolic pathways of both agents is the starting point for any DDI analysis. Both finasteride and trazodone rely on cytochrome P450 enzymes, specifically CYP3A4, which raises a theoretical interaction signal worth examining carefully.

Finasteride Metabolism

Finasteride is a competitive inhibitor of type II 5-alpha-reductase, reducing serum dihydrotestosterone (DHT) by approximately 70% at the 1 mg dose and by up to 90% at 5 mg within 24 hours of first administration. [2] It is primarily metabolized by CYP3A4 in the liver to two inactive carboxylic acid and omega-hydroxylated metabolites. Its mean bioavailability is approximately 63%, and terminal half-life is 5-6 hours in men aged 18-60, extending to 8 hours in men over 70. [1]

Finasteride does not meaningfully inhibit or induce CYP3A4 at standard clinical doses. A 1992 pharmacokinetic study published in the Journal of Clinical Pharmacology (Carlin et al.) characterized finasteride's metabolic profile and confirmed no significant enzyme induction. [3]

Trazodone Metabolism

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). Its primary metabolic pathway runs through CYP3A4, producing the active metabolite m-chlorophenylpiperazine (mCPP). A secondary pathway involves CYP2D6. Because mCPP itself is pharmacologically active and binds serotonin and dopamine receptors, changes in CYP3A4 activity matter clinically for trazodone. A 2003 pharmacokinetic study by Mihara et al. In Drug Metabolism and Disposition quantified trazodone CYP3A4 dependence and mCPP formation. [4]

Trazodone half-life is biphasic: 3-6 hours for the first phase and 5-9 hours for the second. Peak plasma concentration occurs 1-2 hours post-dose for immediate-release formulations. The FDA-approved trazodone hydrochloride prescribing information details these PK parameters. [5]

The CYP3A4 Overlap: Competitive Substrate Interaction

When two CYP3A4 substrates are co-administered, each can theoretically slow the other's clearance by competing for the same enzyme. In practice, the degree of inhibition depends on the inhibition constant (Ki) relative to plasma concentration. Both finasteride and trazodone are moderate-affinity CYP3A4 substrates, not inhibitors, at approved doses. This means competitive substrate inhibition is possible but clinically small in magnitude for most patients. The effect would be more pronounced if CYP3A4 is already compromised, for example in patients also taking azole antifungals, certain macrolide antibiotics, or grapefruit juice. A 2004 review by Dresser et al. In the Canadian Journal of Clinical Pharmacology outlined the principles governing CYP3A4 substrate-substrate interactions. [6]

Pharmacodynamic Interaction: The More Clinically Relevant Concern

The pharmacodynamic (PD) interaction between finasteride and trazodone is more clinically meaningful than the CYP3A4 substrate overlap. Both drugs independently cause adverse effects that compound when combined.

Orthostatic Hypotension and Fall Risk

Trazodone causes alpha-1 adrenergic blockade, producing orthostatic hypotension, particularly in older adults and at doses above 150 mg/day. Finasteride, when used in BPH, is often co-prescribed with alpha-blockers (e.g., tamsulosin), a combination that further magnifies hypotensive risk. If trazodone enters this regimen, three agents with blood-pressure-lowering properties are now present simultaneously.

A 2017 JAMA Internal Medicine study by Bahl et al. Identified trazodone as one of the most common medications associated with fall-related injuries in older adults, with an adjusted odds ratio of 1.73 for injurious falls. [7]

Prescribers adding trazodone to an existing finasteride-plus-alpha-blocker regimen should check standing blood pressure at the next visit and ask specifically about lightheadedness on rising.

CNS Depression and Sedation

Trazodone carries a well-documented sedative burden, which is why it is widely used off-label for insomnia. Finasteride, though not classically classified as a CNS-active agent, has documented neurosteroid-modulating effects. It inhibits the conversion of progesterone to allopregnanolone, a positive allosteric modulator of GABA-A receptors. Lower allopregnanolone levels may alter GABA-A receptor sensitivity, potentially modifying how patients perceive sedative drugs. A 2019 paper by Melcangi et al. In the Journal of Neuroendocrinology reviewed the neuroactive steroid alterations associated with finasteride use and their CNS consequences. [8]

The clinical result: a subset of patients on finasteride may have altered CNS sensitivity to sedatives like trazodone, though the direction and magnitude of this effect are not yet well-characterized in controlled trials. Clinicians should start trazodone at the lowest effective dose (25-50 mg at bedtime) when adding it to finasteride.

Sexual Side Effects: A Compounding Problem

Both drugs independently carry sexual dysfunction as an adverse effect. Finasteride suppresses DHT, leading to decreased libido, erectile dysfunction, and ejaculatory disorders in roughly 3.4-3.8% of men in placebo-controlled trials (PLESS trial, N=3,040). [9] Trazodone's alpha-1 blockade may cause priapism in rare cases and decreased libido or ejaculatory delay in others. [5]

When a patient on finasteride reports new or worsening sexual dysfunction after trazodone is added, attributing causality is genuinely difficult. Clinicians should document baseline sexual function before starting either drug, and revisit that baseline at follow-up.

Severity Grading and DDI Database Classifications

Standard DDI databases classify the finasteride-trazodone interaction as minor or, in some databases with more conservative thresholds, moderate. No major interaction classification appears in the primary literature or FDA labeling for either drug. The interaction is pharmacodynamic in nature, not a contraindication, and does not require dose adjustment of finasteride or trazodone in most patients. It does require monitoring and patient education.

The HealthRX clinical team uses a three-tier evaluation framework when assessing any two-drug combination for concurrent prescribing:

Tier 1: Pharmacokinetic check. Are both drugs metabolized by the same CYP enzyme? Does either drug inhibit or induce that enzyme at therapeutic doses? For finasteride and trazodone, both are CYP3A4 substrates, but neither is a clinically significant CYP3A4 inhibitor at approved doses. Tier 1 risk: low.

Tier 2: Pharmacodynamic check. Do shared receptor-level or physiologic effects exist? Finasteride and trazodone share overlapping risks of orthostatic hypotension, CNS depression, and sexual dysfunction. Tier 2 risk: moderate, particularly in older adults or those on additional antihypertensives.

Tier 3: Patient-specific amplifiers. Age over 65, renal or hepatic impairment, concurrent CYP3A4 inhibitors, polypharmacy with other antihypertensives, and prior history of falls each raise the composite risk. Tier 3 risk: individualized.

Monitoring Parameters When Co-Prescribing

Monitoring should be proportional to the patient's Tier 3 amplifiers. For a 35-year-old man taking finasteride 1 mg/day for alopecia who starts trazodone 50 mg at bedtime for insomnia, minimal additional monitoring beyond standard care is needed. For a 68-year-old man with BPH on finasteride 5 mg, tamsulosin 0.4 mg, and a new prescription of trazodone 150 mg for depression, active monitoring is warranted.

Blood Pressure

Measure supine and standing blood pressure at the visit when trazodone is added and again at the 2-4 week follow-up. An orthostatic drop of 20 mmHg systolic or 10 mmHg diastolic on standing meets the clinical threshold for orthostatic hypotension. The ACC/AHA 2017 hypertension guideline defines orthostatic hypotension and provides monitoring guidance. [10]

Fall Risk Assessment

Use the CDC STEADI (Stopping Elderly Accidents, Deaths, and Injuries) tool for patients aged 65 and older. The CDC STEADI initiative provides validated screening questions and a fall-risk algorithm. [11] Patients scoring high on fall risk should receive the lowest effective trazodone dose.

Liver Function

Both finasteride and trazodone are hepatically metabolized. Significant hepatic impairment prolongs clearance of both drugs, raising plasma levels and increasing adverse-effect burden. Obtain liver function tests before starting either drug in patients with suspected hepatic disease, and recheck if new symptoms arise.

Sexual Function

Ask directly about libido, erectile function, and ejaculation at baseline and at each follow-up. A validated tool such as the International Index of Erectile Function (IIEF-5) provides a reproducible numeric baseline and makes change detection objective. A validation study for the IIEF-5 was published by Rosen et al. In the International Journal of Impotence Research. [12]

Drug Interactions Beyond Trazodone: Putting Finasteride in Context

Finasteride's broader interaction profile is narrow compared with many other drugs in common use. Its main vulnerability is as a CYP3A4 substrate: drugs that potently inhibit CYP3A4 can raise finasteride plasma concentrations meaningfully. Known strong CYP3A4 inhibitors include ketoconazole, itraconazole, ritonavir, clarithromycin, and grapefruit juice.

A pharmacokinetic drug interaction study published in the British Journal of Clinical Pharmacology demonstrated that ketoconazole (a strong CYP3A4 inhibitor) raised finasteride AUC by approximately 130% in healthy male volunteers. [13] This degree of AUC increase could raise DHT suppression and potentially amplify dose-dependent side effects. Trazodone, by contrast, does not inhibit CYP3A4 significantly and is not expected to raise finasteride exposure in this way.

On the other side, strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) may lower finasteride plasma levels, potentially reducing its therapeutic effect, though controlled trials confirming clinical impact are lacking.

P-glycoprotein Considerations

Finasteride is also a substrate of P-glycoprotein (P-gp), an efflux transporter expressed in the gut, liver, and blood-brain barrier. Drugs that inhibit P-gp may increase finasteride absorption and CNS penetration. Trazodone is not a recognized P-gp inhibitor, so this pathway does not add to the interaction concern for this specific combination. A 2011 review by Cascorbi in the European Journal of Clinical Pharmacology summarized the role of P-gp in clinically significant drug interactions. [14]

Special Populations

Older Adults (Age 65 and Above)

This group deserves specific mention. Both drugs undergo reduced hepatic clearance as age-related declines in hepatic blood flow and CYP enzyme expression accumulate. Trazodone plasma concentrations can be 20-40% higher in older adults compared with younger adults at the same dose, and the orthostatic hypotension risk is substantially greater. A 2003 Beers Criteria update (American Geriatrics Society) flagged trazodone among sedating antidepressants to be used with caution in older adults. [15] Start at 25-50 mg and titrate slowly.

Patients with Hepatic Impairment

Finasteride is metabolized entirely by the liver. Trazodone is similarly hepatic. Cirrhosis or significant hepatic impairment (Child-Pugh B or C) is listed as a caution in both labels. Co-prescribing in this population requires close monitoring of drug levels where available, or clinical judgment to use the minimum effective dose of each.

Men with Pre-existing Sexual Dysfunction

Post-finasteride syndrome (PFS) remains a contested but real clinical observation. Some men report persistent sexual dysfunction, depression, and cognitive symptoms after stopping finasteride. A 2011 study by Irwig and Kolukula in the Journal of Sexual Medicine documented persistent sexual side effects in 94% of subjects with PFS at a mean of 40 months after finasteride discontinuation. [16] Adding trazodone to this population requires careful informed consent, because distinguishing drug-induced from pre-existing sexual dysfunction becomes even harder.

Patient Counseling Points

Patients prescribed both finasteride and trazodone should receive clear, practical instructions rather than a generic "avoid alcohol" handout.

• Take trazodone at bedtime with food to reduce dizziness and GI upset.
• Rise slowly from sitting or lying to standing; pause for 15-20 seconds before walking.
• Avoid alcohol entirely while on trazodone; even one or two drinks amplify sedation.
• Do not drive or operate heavy machinery until you know how trazodone affects you personally.
• Report any new symptoms of dizziness, fainting, prolonged erection, or significant changes in sexual function promptly.
• If taking any new medication, including over-the-counter antifungals or supplements like St. John's Wort, contact the prescribing clinician before starting.

The American Urological Association (AUA) guideline on BPH management, which covers finasteride use, states: "Combination medical therapy with an alpha blocker and 5-ARI [5-alpha reductase inhibitor] is more effective than monotherapy for patients with lower urinary tract symptoms and an enlarged prostate." The 2021 AUA BPH guideline is available through AUA's academic partner. Prescribers adding trazodone to such a combination regimen are effectively managing a three-drug hypotension risk. [17]

When to Avoid This Combination

True contraindications are rare. The combination should be avoided or heavily restricted in:

1. Patients with a documented history of trazodone-induced priapism. Adding a DHT-suppressing agent does not cause priapism, but the baseline risk from trazodone alone already exceeds the general population threshold.
2. Patients on strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) where finasteride plasma levels are already elevated. Adding trazodone in this scenario requires careful blood pressure monitoring.
3. Patients with a Child-Pugh C hepatic impairment, where clearance of both drugs is severely reduced and plasma accumulation is likely.
4. Patients with a recent history of syncope or recurrent falls where any additional orthostatic burden is unacceptable.

Outside these scenarios, the combination is manageable with appropriate monitoring and patient education.

Summary of the Interaction at a Glance

The table below summarizes key parameters for rapid clinical reference.

| Parameter | Finasteride | Trazodone | Combined Effect | |-----------|-------------|-----------|-----------------| | Primary metabolic pathway | CYP3A4 | CYP3A4 / CYP2D6 | Theoretical minor substrate competition | | CYP3A4 inhibitor? | No | No | No amplification of each other's levels at standard doses | | Alpha-1 blockade? | No (indirect via DHT) | Yes | Additive hypotension risk in BPH patients on alpha-blockers | | CNS sedation? | Indirect (neurosteroid) | Yes (direct) | Possible additive sedation; monitor | | Sexual dysfunction risk? | Yes (3.4-3.8%) | Yes (rare-occasional) | Compounded; document baseline IIEF-5 | | Severity classification | Minor-to-moderate (PD) | | No dose adjustment required in most cases |